In line with these findings, Valverde et al. found that combined celecoxib and cetuximab treatment inhibited growth and induced apoptosis in non-KRAS-mutated CRC cells in vitro and in mouse xenografts via impairment of the EGFR/RAS/β-catenin/FOXM1 signaling axis [194]. This evidence concerns the gene EGFR and colorectal carcinoma.